Changing Strategies for the Management of Invasive Fungal Infections
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The frequency of invasive fungal infections (IFIs) has increased with the increase in number of high‐risk patients. United States trends in mortality due to invasive mycoses showed a striking increase in the past 2 decades. Human immunodeficiency virus–associated opportunistic mycoses accounted for part of the increase, as did mycoses in other immunocompromised populations. Those at‐risk populations include recipients of solid organ transplants or hematopoietic stem cell transplants, those with hematologic malignancies, and others receiving immunosuppressive treatment. Infections due to Candida sp are the most common fungal infections. The mortality rate due to invasive aspergillosis has risen steadily, with a 357% increase from 1980–1997. Depending on whether an IFI is possible, probable, or proved, three treatment strategies are available: prophylactic, empiric, and specific. Options for preventing and treating IFIs have increased, with four classes of antifungal agents available: polyenes, azoles, nucleoside analogs, and echinocandins. The effectiveness of the polyene amphotericin B deoxycholate (the standard for > 40 yrs) is limited by toxic effects, notably renal and infusion‐related toxicity. Three lipid formulations are approved for the treatment of IFIs in patients refractory to or intolerant of amphotericin B: amphotericin lipid complex, amphotericin B colloidal dispersion, and liposomal amphotericin B. The nucleoside analog class contains only flucytosine—an antimetabolite targeting the nucleus of the fungal cell and generally not given as monotherapy because of frequent development of resistance. The azoles debuted with ketoconazole, followed by fluconazole, itraconazole, and voriconazole. Fluconazole is largely active against Candida sp and Cryptococcus neoformans; itraconazole's activity is largely against moulds, such as Aspergillus, and dimorphic fungi, such as Histoplasma and Blastomyces; and voriconazole is active against both yeasts and moulds. The echinocandin class has one drug approved for clinical use—caspofungin, which targets the fungal cell wall. Deciding which antifungal agent to use involves weighing such clinical factors as mycoses susceptibility and drug toxicity, as well as pharmacoeconomic considerations. Besides the price of the drug, the cost of antifungal therapy includes costs of mortality associated with failed treatment, prolonged hospitalization and treatment related to complications, and additional antifungal treatment to compensate for primary treatment failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · cited 1×
“Fluconazole also has been compared with amphotericin B as a treatment for candidemia.(51) The authors of this study evaluated 206 patients who had a positive blood culture for Candida sp, a neutrophil count of 500/mm(3) or greater, and no immunodeficiency.”
MethodWalsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“To evaluate the clinical effectiveness and safety of voriconazole, one group evaluated 116 patients confirmed or suspected to have invasive aspergillosis who were treated with voriconazole as primary or salvage therapy after failure with or intolerance to other antifungal therapy.(54) In this open-label, noncomparativ…”
MethodVermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., & Hollis, R. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.852-856.2002 · Cited by 331
Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321
The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“For example, a 1998 report estimated that nosocomial candidemia costs in the United States are about $200 million/year.(58) That estimate, however, was based on an underestimation of the incidence of the illness.”
BackgroundShould Vascular Catheters Be Removed from All Patients with Candidemia? An Evidence-Based Review
Nucci, M., & Anaissie, E. (2002) · Clinical Infectious Diseases · doi:10.1086/338714 · Cited by 175 · cited 1×
“However, in a review that examined 203 studies of candidemia, the authors found very few studies that evaluated the outcome of candidemia in relation to catheter removal, and conflicting results among those that did.(9) Nevertheless, the Infectious Diseases Society of America (IDSA) recommends removing all vascular ca…”
ResultEstimating the Cost of Nosocomial Candidemia in the United States
Miller, L. G., Hajjeh, R. A., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/319613 · Cited by 109 · cited 1×
“Clearly, treatment options with improved efficacy, safety, and tolerability would lower the cost of the illness.(59) Treatment of systemic fungal infections with conventional amphotericin B is frequently complicated by severe nephrotoxicity that is often dose limiting and irreversible, and prolongs hospital stay with…”
Background
Cited by
Pinto, E., Vale-Silva, L., Cavaleiro, C., & Salgueiro, L. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.010538-0 · Cited by 699
El-Saber Batiha, G., Alkazmi, L. M., Wasef, L. G., Beshbishy, A. M., Nadwa, E. H., & Rashwan, E. K. (2020) · Biomolecules · doi:10.3390/biom10020202 · Cited by 643
Pinto, E., Pina-Vaz, C., Salgueiro, L., Gonçalves, M. J., Costa-de-Oliveira, S., Cavaleiro, C., Palmeira, A., Rodrigues, A., & Martinez-de-Oliveira, J. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46443-0 · Cited by 330
Single dose and multiple dose studies of itraconazole nanoparticles
Vaughn, J. M., McConville, J. T., Burgess, D., Peters, J. I., Johnston, K. P., Talbert, R. L., & Williams, R. O. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.01.006 · Cited by 85
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62
Metadata
- Authors
- Rapp, R. P.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2004-02
- Volume
- 24
- Issue
- 2P2
- Pages
- 4S-28S; quiz 29S
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2035034865
- Cited by
- 125
- References
- 17
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.